Aeglea amends Paragon agreement, commits to annual 1% option grants for 2023-2024

Spyre Therapeutics, Inc.

Annual option grant of 1% of outstanding Aeglea common stock (fully-diluted) to Parapyre for calendar years 2023 and 2024.
Grant date set to last business day of each applicable year; options vest immediately and have a 10-year term.
Paragon and Parapyre each hold less than 5% of Aeglea's capital stock; Fairmount (>5% holder) controls Paragon's board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.